Showing 1681-1690 of 2403 results for "".
Currents: Picture This: Clinical Updates for Dermatologists
https://practicaldermatology.com/topics/atopic-dermatitis/currents-picture-this-clinical-updates-for-dermatologists/23609/SRT: Innovating a Proven Treatment for Skin Cancer Treatment
https://practicaldermatology.com/topics/skin-cancer-photoprotection/srt-innovating-a-proven-treatment-for-skin-cancer-treatment/20645/Innovating upon a tried-and-true technology, an updated device is available for dermatologists to use to fight skin cancer.Hidradenitis Suppurativa: Seeking More Pieces to the Puzzle
https://practicaldermatology.com/topics/rare-disease/hidradenitis-suppurativa-seeking-more-pieces-to-the-puzzle/23669/Evidence suggests that integrated approaches to care may yield best results for many patients.New Directions in Acne Care
https://practicaldermatology.com/topics/acne-rosacea/new-directions-in-acne-care/23515/Recent developments and therapeutic advancements continue to improve outcomes in the management of this common, inflammatory disease.Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/annual-trends-in-medicare-part-d-prescription-claims-for-guselkumab-20182020/28861/Jachin Wu, MD, FAAD, and colleagues talk about Medicare claims for guselkumabPipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigBenchside Dispatches Psoriasis
https://practicaldermatology.com/topics/psoriasis/benchside-dispatches-psoriasis/20922/An interview with Alice Gottlieb, MD, PhDWeighing the Prospects of Biosimilars
https://practicaldermatology.com/columns/clinical-focus-1/weighing-the-prospects-of-biosimilars/21477/If they are found to be comparable to the “originators,” biosimilar agents may offer patients significant therapeutic benefits as well as cost efficiency.Angioleiomyoma in a Rare Location
https://practicaldermatology.com/topics/other-dermatology/angioleiomyoma-in-a-rare-location/24012/A minimally invasive treatment is used to treat a tumor in a cosmetically sensitive area.Understanding PML and Risks Associated with Biologic Therapies
https://practicaldermatology.com/topics/psoriasis/PD0509_10-php/22832/A swarm of controversy has enveloped biologics due to concerns about progressive multifocal leukoencephalopathy.